A share price of Janux Therapeutics Inc [JANX] is currently trading at $44.11, down -1.08%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JANX shares have gain 8.62% over the last week, with a monthly amount drifted -22.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on December 03, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $70 from $63. Previously, BTIG Research reaffirmed its Buy rating on December 03, 2024, and elevated its price target to $100. On November 22, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $79 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $69 on October 24, 2024. Stifel initiated its recommendation with a Buy and recommended $70 as its price target on September 06, 2024. Scotiabank started tracking with a Sector Perform rating for this stock on May 30, 2024, and assigned it a price target of $47. In a note dated March 21, 2024, BTIG Research initiated an Buy rating and provided a target price of $62 on this stock.
Janux Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $7.79 and $71.71. Currently, Wall Street analysts expect the stock to reach $70.25 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $44.11 at the most recent close of the market. An investor can expect a potential return of 59.26% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Trailing Twelve Months sales for Janux Therapeutics Inc [NASDAQ:JANX] were 13.05M which represents -82.56% decline. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -6.59%, Pretax Profit Margin comes in at -4.64%, and Net Profit Margin reading is -4.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.1 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.87 points at the first support level, and at 41.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.40, and for the 2nd resistance point, it is at 46.68.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Janux Therapeutics Inc [NASDAQ:JANX] is 38.80. As well, the Quick Ratio is 38.80, while the Cash Ratio is 1.56. Considering the valuation of this stock, the price to sales ratio is 195.37, the price to book ratio is 3.52.
Transactions by insiders
Recent insider trading involved Campbell David Alan, President and CEO, that happened on Jan 07 ’25 when 5000.0 shares were sold. Officer, Campbell David Alan completed a deal on Jan 07 ’25 to buy 5000.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 13334.0 shares on Jan 02 ’25.
